Biosimilars uptake slower in US than Europe | Kisqali outperformed stand-alone hormonal therapy against breast cancer | GSK seeks expanded indication for asthma biologic
November 9, 2017
DIA Global SmartBrief
News on diagnostic and therapeutic innovations and regulatory science
Top Story
Biosimilars uptake slower in US than Europe
Uptake of biosimilars has been slow in the US, according to a session at the American College of Rheumatology annual meeting, where physician Roy Fleischmann noted, "There is no benefit in cost to patients and no improvement in access to biologic therapy to patients." Europe has had more success with the drugs, where a biosimilar for Remicade, or infliximab, costs 69% less in Norway than the reference biologic.
Specialty Pharmacy Times (11/7) 
LinkedIn Twitter Facebook Google+ Email
7 keys: Put real-world evidence into action
Life sciences organizations need to know how their therapies work in the real world once clinical trials end. And these seven key components to standardizing real-world data and analytics platforms are how they get started. Read the paper, Institutionalizing Real World Evidence.
Kisqali outperformed stand-alone hormonal therapy against breast cancer
Kisqali outperformed stand-alone hormonal therapy against breast cancer
(Sebastien Bozon/Getty Images)
A late-stage trial of Novartis' breast cancer drug Kisqali in combination with hormonal therapies in premenopausal women was able to stop the progression of hormone-receptor positive, human epidermal growth factor receptor-2 negative advanced breast cancer longer than hormonal therapy alone, according to the company.
Reuters (11/8) 
LinkedIn Twitter Facebook Google+ Email
GSK seeks expanded indication for asthma biologic
GlaxoSmithKline submitted a supplemental new drug application to the US FDA for Nucala, or mepolizumab, as an add-on to maintenance therapy for eosinophilic chronic obstructive pulmonary disease. The interleukin-5 antagonist was approved in 2015 to treat asthma caused by eosinophilic inflammation.
PharmaTimes (U.K.) (11/8) 
LinkedIn Twitter Facebook Google+ Email
Merck, Pfizer's rare skin cancer drug introduced in UK
Merck & Co. and Pfizer announced the availability in the UK of Bavencio, or avelumab, which is indicated for the treatment of metastatic Merkel cell carcinoma. Until now, the sole option for treatment of this rare, aggressive skin cancer has been chemotherapy, the companies said.
PharmaTimes (U.K.) (11/6) 
LinkedIn Twitter Facebook Google+ Email
Asia Pacific
China intensifies efforts to halt illegal internet drug sales
China intensifies efforts to halt illegal internet drug sales
China is stepping up its monitoring of the internet to halt illegal drug and medical device sales. Local China FDA officials are expected to use social media sites to share information with the public.
Regulatory Focus (11/7) 
LinkedIn Twitter Facebook Google+ Email
FDA issues warning letter to Lupin's 2 formulation facilities in India
The FDA sent a combined warning letter to Lupin citing violations in good manufacturing practices at its facilities in Goa and Indore, India. The company said the product supply from the facilities will not be interrupted despite the warnings, although new product approvals from the plants will likely be delayed.
In-Pharma Technologist (11/7) 
LinkedIn Twitter Facebook Google+ Email
Studies show Takeda vaccine effective against all 4 dengue strains
Studies show Takeda vaccine effective against all 4 dengue strains
(Norberto Duarte/AFP/Getty Images)
A dengue fever vaccine developed by Takeda shows sustained antibody responses against all four strains of the virus, according to 18-month data published in the journal Lancet Infectious Diseases. Takeda is testing a two-dose regimen of the vaccine in a late-stage trial to achieve a faster rate of response.
PharmaPhorum (U.K.) (11/7) 
LinkedIn Twitter Facebook Google+ Email
North America
Senators ask Allergan CEO for details on patent transfer
A group of Senate Democrats asked Allergan CEO Brent Saunders to disclose the terms of the drugmaker's deal to transfer patents on dry-eye drug Restasis to a Native American tribe, shielding the patents from Patent Trial and Appeal Board review, and asked whether the Allergan plans similar deals.
Reuters (11/7) 
LinkedIn Twitter Facebook Google+ Email
Certain sizes of Innova, Eluvia stents recalled by Boston Scientific
A recall was initiated by Boston Scientific involving its 180- and 200-mm Innova self-expanding stent system and 150-mm Eluvia drug-eluting vascular stent. The recall was issued because of the number of complaints associated with partial stent deployment, which may cause prolongation of the implant procedure or vessel trauma and could require major surgery.
Drug Delivery Business News (11/7) 
LinkedIn Twitter Facebook Google+ Email
FDA issues proposal to reclassify needle destruction device
The needle destruction device, currently named the "sharps needle destruction device," would be reclassified from a Class III device to a Class II device with special controls under a proposed order issued by the FDA. The order was put forward as part of the 2014-2015 strategic priority of the agency's Center for Devices and Radiological Health to review Class III devices for possible reclassification.
Regulatory Focus (11/6) 
LinkedIn Twitter Facebook Google+ Email
DIA News
DIA pharmacovigilance training
Get the information you need to ensure your pharmacovigilance programs are built on a foundation supported by strong strategic planning and practical decision-making. Expand your knowledge of all new regulations, regulatory pathways, data sources, technologies and cutting-edge therapeutic products, and discover how to adapt your pharmacovigilance and risk management strategies to remain effective while keeping pace with change. Attend DIA’s Pharmacovigilance and Risk Management Strategies Conference, Jan. 22-24, in Washington, D.C.
LinkedIn Twitter Facebook Google+ Email
Save now on these upcoming events
LinkedIn Twitter Facebook Google+ Email
Learn more about DIA:
About DIA | Meetings & Trainings | News & Publications | Membership
One must need to be strong; otherwise, one never becomes strong.
Friedrich Nietzsche,
LinkedIn Twitter Facebook Google+ Email
Sign Up
SmartBrief offers 200+ newsletters
Learn more about the SmartBrief audience
Subscriber Tools:
Contact Us:
Advertising  -  Wynn Hansen
P: 202.470.1149
Editor  -  Lisa Gough
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2017 SmartBrief, Inc.®
Privacy policy |  Legal Information